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Introduction
Synchronously presenting carcinomas provide a chal-
lenge for the radiation oncologist, particularly in the
chest. Such cases are rarely reported in literature, and
treatment guidelines are not well defined. Approximately
0.5% of patients with BC experience synchronous lung
cancers, and 0.5% of patients with lung cancer present
with synchronous primary lung malignancies.1,2
Jin et al3 describe the challenges in treating 3 primary
thoracic cavity cancers and the solutions provided by
modern therapies such as stereotactic ablative radio-
therapy. Even when tumor volume or location limit the
applicability of such techniques, IMRT allows for positive
outcomes and appropriate dose limits to the adjacent or-
gans at risk. Kim et al4 compared the IMRT and
volumetric-modulated arc therapy (VMAT) plans to
3DCRT plans for synchronous bilateral BC and
established that IMRT provided superior planning target
volume (PTV) dose coverage, whereas VMAT demon-
strated superior treatment efficiency.
We present the case of a postmenopausal female with
synchronous HER2-positive breast and atypical carcinoid
lung cancers. To our knowledge, no prior reported case
exists. She was treated with adjuvant systemic therapy
involving trastuzumab followed by concurrent 3DCRT
and IMRT, targeted to each disease site, respectively. The
patient provided informed consent to report the details of
her case, including images.
Case
A 63-year-old asymptomatic postmenopausal female,
with no significant past medical history, presented with a
new left breast lesion detected on screening mammog-
raphy (Fig 1a,b). Her work-up (Table 1) included the
diagnosis of a synchronous lung primary tumor (Fig 1c).
The patient underwent a left breast lumpectomy with
sentinel lymph node biopsy and subsequent right upper
lobectomy with mediastinal lymph node dissection, with
final diagnoses of hormone receptor-negative HER2-
positive pT1cN0(sn)M0 (stage IA, American Joint
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Committee on Cancer, eighth edition) invasive ductal
carcinoma of the left breast and pT2aN2cM0 (stage IIIA,
American Joint Committee on Cancer, eighth edition)
atypical carcinoid tumor of the right upper lobe.
She later received adjuvant systemic therapy with
docetaxel, carboplatin, and trastuzumab (TCH),
consisting of docetaxel (75 mg/m2) plus carboplatin
(area under curve, 6 mg/mL/min) every 3 weeks for 5
cycles (sixth cycle omitted owing to poor tolerance)
concurrently with trastuzumab, followed by trastuzumab
to complete a year of treatment. Heart function was
monitored with multigated acquisition cardiac pool
imaging to assess left ventricular ejection fraction and
wall motion. The left ventricular ejection fraction
decreased from 70% to 56% after 6 months of trastu-
zumab but was stable for the remainder of treatment.
Her Eastern Cooperative Oncology Group perfor-
mance status was zero when first evaluated by radiation
oncology, and she complained of a mild postsurgical
cough. She was offered adjuvant left whole breast RT
with surgical cavity boost to complete breast conservation
therapy, concurrently with adjuvant right lung and
mediastinal irradiation.
After radiopaque markers were placed over the
lumpectomy scar and the clinical breast borders, she
underwent a 2.5-mm thickness free-breathing noncontrast
CT simulation scan while immobilized on a breast board
in the supine position, with both arms above the head
(Fig 2).
The left breast and lumpectomy surgical cavity clinical
target volumes were delineated according to the Radiation
Therapy Oncology Group (RTOG) BC atlas guidelines,5
Figure 1 Left breast mammogram showing lesion (white arrow): (a) craniocaudal view, (b) medio-lateral oblique view, (c) positron
emission tomography (PET)/computed tomography (CT) scan axial views of right paratracheal lesion standardized uptake value (SUV)
4.6 (white arrow) and left breast lesion SUV 6.4 (red arrow).
Advances in Radiation Oncology: SeptembereOctober 2020 Synchronous breast and lung cancers 1077
Downloaded for Anonymous User (n/a) at Washington University in Saint Louis Bernard Becker Medical Library from ClinicalKey.com by Elsevier on November 05, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
with a 5-mm expansion for the PTV. The right lung
clinical target volume was delineated around the right
upper lobe bronchial stump and mediastinal lymph node
stations 4R, 10R, and 7. The PTV included 5-mm
medio-lateral, 5-mm dorso-ventral, and 10-mm
craniocaudal expansions. Organs at risk delineated
included each lung and the heart.
A composite plan was generated with Eclipse (v13.6
Varian Medical Systems) to deliver 95% of the prescribed
dose (50 Gy, 2 Gy fractions) to 95% of the whole left
breast PTV, 100% of the prescribed sequential boost dose
(10 Gy, 2 Gy fractions) to 95% of the surgical cavity, and
concurrently 95% of the prescribed dose (50 Gy, 2 Gy
fractions) to 100% of the right lung and mediastinum
PTV. The planning objective was to minimize
cardiopulmonary doses as much as reasonably possible
while treating targets well.
A 3DCRT breast plan was generated using 2
opposed tangential fields with 18 MV photons and
field-in-field technique to ensure dose homogeneity
(95%-107% dose levels relative to 100% prescription
point per International Committee on Radiation Units
and Measurements-50 guidelines). A mix of 6 and 18
MV photons was used for the boost. The left lung and
the heart were shielded using multileaf collimators. A
5-field IMRT right lung treatment plan using 6 MV
photons was also created. Figure 3 shows beam
arrangement, color wash dose, and isodose lines.
Figure 4 shows the corresponding dose volume
histogram, and Table 2 summarizes key values.
Radiation treatment (MV image guided) began 4
weeks after the last cycle of TCH. During treatment, the
patient reported expected acute gastrointestinal
(odynophagia), pulmonary (dry cough), and dermatologic
(erythema) toxicities, all grade 1 per the Common
Terminology Criteria for Adverse Events. All toxicities
resolved at 1 month, except for cough, which lasted 6
months. Her follow-up CT scans showed RT-related
changes at the periphery of the right medial and left
upper lungs.
Discussion
An increase in incidence of primary breast tumors in
the setting of metachronous primary lung carcinoid
Table 1 Patient workup including all relevant imaging tests and procedures in chronological order from top to bottom
Test/procedure (chronological order) Results
Screening mammography (Fig 1a,b) 1.0  0.9  0.6 cm left breast lesion at 12 o’clock, 3 cm from the nipple
US guided biopsy of the left breast lesion Moderately differentiated adenocarcinoma, estrogen receptor and
progesterone receptor negative, HER2 amplified
PET/CT scan (Fig 1c) Known left breast lesion (SUV 6.4) and a 2.1  1.5 cm FDG-avid right
paratracheal lesion (SUV 4.6)
EBUS with FNA of the right paratracheal lesion Low-grade endocrine tumor, synaptophysin and chromogranin positive
Left breast lumpectomy with SLNB 1.5 cm invasive ductal carcinoma, Nottingham system grade II/III,
negative margins, 0 of 4 lymph nodes positive
Mediastinoscopy No evidence of metastatic disease
Right upper lobectomy with MLND 3.1 cm atypical carcinoid tumor, lymphovascular invasion present,
negative margins, positive lymph node station 4R, negative lymph node
stations 7, 8, 9, and 11R
Abbreviations: CT Z computed tomography; EBUS Z endobronchial ultrasound; FDG Z fluorodeoxyglucose; FNA Z fine needle aspiration;
HER2Z human epidermal growth factor receptor 2; MLNDZ mediastinal lymph node dissection; PETZ positron emission tomography; SLNBZ
sentinel lymph node biopsy; SUV Z standardized uptake value; US Z ultrasound.
Figure 2 Radiopaque markers indicating lumpectomy scar and clinical breast borders (medial, midline over sternum; lateral, mid-
axillary line; cranial, inferior aspect of the clavicular head; and caudal, 2 cm below the inframammary fold) (left). Patient on a breast
board in the supine position, both arms above the head (right).
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tumors has been observed.6 Our patient provided a
challenging case for her multidisciplinary care team.
The decision whether to provide adjuvant
chemotherapy and/or RT to a stage IIIA atypical carcinoid
tumor of the lung is complex owing to lack of prospective
randomized data. In a retrospective review of 73 patients
with lung neuroendocrine tumors treated with surgical
resection, 7 patients received adjuvant chemotherapy
and/or RT due to lymph node involvement, local
invasion, or involved margins.7 However, only 1 of 7
patients was alive at 10 years. Typical chemotherapy
regimens include cisplatin/etoposide, carboplatin/
etoposide, or temozolomide.8 Our patient received
adjuvant docetaxel and carboplatin, which were both
reported in the treatment of atypical carcinoid tumors and
selected because both agents are active in breast
and lung cancer (including carcinoid).9 In pN2 lung
adenocarcinoma, postop RT has shown benefits in terms
of overall survival (OS).10-12 Given the more aggressive
nature of atypical carcinoid, the presence of positive
nodes, and lack of data, we extrapolated lung
adenocarcinoma adjuvant RT findings. The patient elected
adjuvant RT over omission when we explained that RT
would likely improve local recurrence but not OS.13
For the radiation oncologist, the most challenging
prospect in the setting of synchronous breast and lung
tumors is limiting heart dose. Current clinical trial
protocols for stage III non-small cell lung cancer
(NSCLC), including the ongoing RTOG 1306 (using
3DCRT or IMRT), specify cardiac dosimetric limits
mostly unchanged since RTOG 0617: V60 (volume
receiving 60 Gy) < 1/3, V45 < 2/3, and V40 < 3/3.
Table 2 shows these limits were all satisfied by the
composite RT plan. Recent trials for BC, such as National
Surgical Adjuvant Breast and Bowel Project (NSABP)
B-51/RTOG 1304 and RTOG 1005, define more stringent
Figure 3 Composite radiation treatment plan illustrating beam arrangements in Eclipse (v13.6 Varian Medical Systems); (a) dose-
color-wash axial and (b) coronal section; (c) isodose lines axial and (d) coronal section.
Figure 4 Composite plan cumulative dose volume histogram (DVH) of planning target volumes (PTVs) (solid red, right lung and
mediastinum; solid green, left whole breast; solid blue, left breast surgical cavity; dotted pink, left lung; dotted orange, right lung; solid
brown, both lungs; dotted blue, whole heart; solid black, left anterior descending (LAD); dotted green, pericardium; solid purple, left
ventricle; dotted purple, right ventricle; solid yellow, left atrium; dotted yellow, right atrium).
Advances in Radiation Oncology: SeptembereOctober 2020 Synchronous breast and lung cancers 1079
Downloaded for Anonymous User (n/a) at Washington University in Saint Louis Bernard Becker Medical Library from ClinicalKey.com by Elsevier on November 05, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
heart dose limits due to a better prognosis of patients with
BC versus patients with lung cancer. In general, the
goals are maximal mean heart dose (MHD) of 4 to 5 Gy,
V25 < 10% and V30 < 10% for left-sided BC.14 In our
plan, the MHD limit was exceeded due to the contribution
from the lung IMRT component, which represents
approximately 75% of the 6.0 Gy MHD.
Remaining below dose limits is crucial, as the risk of
ischemic heart disease in women after breast RT is
well-studied. Darby et al15 established that this risk in
women treated before the 3DCRT era starts within 5 years
after exposure, lasts for at least 20 years, and is
proportional to the MHD, with a linear increase in major
coronary events of 7.4% per Gy. Van den Bogaard et al16
showed that the left ventricle V5 after breast conservation
surgery is a better predictor for acute coronary events than
MHD.
In RTOG 0617 for stage III NSCLC, heart dose was
associated with worse OS at 2-year median follow-up,
suggesting RT-induced cardiac disease develops sooner
than historically understood.17,18 Speirs et al19 reported on
patients with locally advanced NSCLC who received
Table 2 OAR composite plan values with limitations per locally advanced lung cancer protocols, single institutions, and breast
cancer protocols. Cardiac structure with radiation dose levels, HR rate of cardiac events, and estimated HR of cardiac events





RTOG 1005 NSABP B-51 (left breast)
Whole heart
Mean 6.0 Gy <20 Gy* 4 Gy (5 Gyy)  4 Gy (5 Gyy)
Max 54.5 Gy
V5 23%
V10 12% 30% (35%y)*
V20 7% 5%









Both lungs (minus PTV)
Mean 13.3 Gy 20-22 Gy*
Max 59.0 Gy
V20 25.0% 37-40%*
Ipsilateral lung (minus PTV)
V20 20% 15% (20%y)* 15% (20%y)*
Contralateral lung
V5 67% 10% (15%y) 15%
Cardiac structure Value HR rate Estimated HR Cardiac structure Value HR rate Estimated HR
Left ventricle Left atrium
Mean 3.4 Gy 1.05/Gy 3.6 Mean 4.9 Gy 1.04/Gy 5.1
V5 15% 1.03/% 15.5 V5 20% 1.05/% 21.0
V30 0% 1.03/% 0.0 V30 3% 1.03/% 3.1
V60 0% 1.03/% 0.0
Whole heart
Mean 6.0 Gy 1.02/Gy 6.1 Right atrium
V5 23% 1.03/% 23.7 Mean 2.0 Gy 1.03/Gy 2.1
V30 5% 1.02/% 5.1 V5 0% 1.02/% 0.0
V60 0% 1.04/% 0.0 V60 0% 1.02/% 0.0
Abbreviations: HR Z hazard ratio; LAD Z left anterior descending; NSABP Z National Surgical Adjuvant Breast and Bowel Project; OAR Z
organs at risk; PTV Z planning target volume; RCIZ Rutgers Cancer Institute of New Jersey; RTOGZ Radiation Therapy Oncology Group; UNC
Z University of North Carolina; Vx Z percentage of the structure volume receiving  x Gy; WashU Z Washington University St Louis.
* Dose limit met.
y Acceptable value per protocol.
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definitive RT alone or with chemotherapy. On
multivariate analysis (MVA), V50 was the strongest
factor independently associated with worse OS and
keeping V50 < 25% (hazard ratio [HR], 1.23; P < .0001)
yielded nearly a 20% absolute improvement in 2-year OS.
Wang et al20 reported on patients with stage III
NSCLC with definitive dose-escalated 3DCRT after
induction chemotherapy with or without concurrent
chemotherapy and suggested dose-dependent RT-related
cardiotoxicity. On MVA, heart doses were significantly
associated with incidence of symptomatic cardiac events
(pericardial effusion, acute coronary syndrome,
pericarditis, significant arrythmia, and heart failure)
adjusted for the competing risk of death (estimated
using baseline cardiac risk). Events were higher with
MHD  20 Gy versus < 10 Gy (HR, 5.47; P < .001), but
OS was not. An MHD < 20 Gy, or lower if possible, was
deemed a reasonable limit, which was also advocated by
Yegya-Raman et al21 based on a retrospective review of
inoperable patients with NSCLC treated with definitive
concurrent chemoRT. On MVA, only baseline cardiac
status and MHD were associated with increased risk of
symptomatic cardiac events (defined by Wang et al20).
When stratified by MHD  20 Gy versus 10 to 20 Gy
versus < 10 Gy, cumulative symptomatic cardiac events
were significantly higher with MHD  20 Gy versus
< 10 Gy (HR, 4.95; P Z .0024). Although no direct
association between MHD and OS was found,
symptomatic cardiac events predicted worse OS. Atkins
et al22 also reported on stage II (unresectable or
inoperable) and stage III NSCLC treated with
multimodality therapy involving RT. In patients without
preexisting coronary heart disease, there was a
significantly higher risk of all-cause mortality with
MHD  10 Gy versus < 10 Gy (HR, 1.34; P Z .014).
Wang et al23 also showed that cardiac events
(pericardial, ischemia, and arrhythmia) were associated
with distinct heart subvolume dose levels and were
detected by 2-year median follow-up, supporting the
possibility of distinct etiologies for RT-induced
cardiotoxicity. The subvolumes (delineated per Feng
et al24) included whole heart, left ventricle, right
atrium, and left atrium. Using HR values from Wang
et al,23 our patient was at highest risk of cardiac
ischemia (HR, 15.5 from left ventricle V5 and HR, 23.7
from whole heart V5) and arrhythmia (HR, 23.7 from
whole heart V5), as summarized in Table 2.
The LAD coronary artery was also contoured per Feng
et al24 as a critical structure for RT-induced cardiac
events. Lind et al25 studied single-photon emission
tomography myocardial perfusion imaging in 69 patients
who underwent RT for left-sided BC and found perfusion
defects in the LAD distribution, pointing to a likely
mechanism of cardiac damage. Copper et al26 suggested
the maximum LAD dose (LADmax) may be more
clinically relevant over the mean LAD dose, as occlusion
of only 1 section of the LAD can result in symptomatic
heart disease and proposed LADmax < 10 Gy. Our
patient’s LADmax was very close at 10.9 Gy.
Limiting heart dose was additionally important, as the
patient’s BC necessitated adjuvant trastuzumab, which
improves disease-free survival and OS in HER2-positive
BC; however, it can induce a statistically significant
increase in congestive heart failure and cardiac
dysfunction, particularly when used with an
anthracycline-based chemotherapy regimen.27
Modalities that possibly could have reduced toxicity to
the heart and lungs are not available at our safety-net
hospital and include motion encompassment (eg,
4-dimensional CT scanning) and respiratory gating
(triggered activation or deactivation of RT delivery).28
Lung radiation was delivered with IMRT, although
VMAT (not available at our institution) is shown to help
reduce heart dose.29 Proton therapy also can theoretically
reduce dose to critical structures; the ongoing RTOG
1308 trial comparing motion-managed proton versus
photon RT in inoperable stage II-IIIB NSCLC is
investigating cardiac toxicity as a primary objective.
Conclusions
Synchronous breast and lung cancers are rare and pose
a technical challenge for RT planning should concurrent
treatment be warranted. Satisfying more stringent cardiac
dose limits than specified by ongoing lung cancer trials is
critical, as patients with lung cancer can develop
RT-related cardiac toxicities within 2 years posttreatment.
Tracking dose levels within cardiac substructures may be
more relevant than whole heart doses. Techniques
employing 3DCRT and IMRT create a composite plan
both safe and practical with minimal acute or subacute
toxicities, as our patient's case shows. Further research is
warranted to investigate best strategies in this unique
patient population.
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